Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance-Reference-Cited by-同舟云学术

Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance

Published:2019-05 Issue:S1 Volume:39 Page:43-62
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Fouassier Laura¹^ORCID,Marzioni Marco²,Afonso Marta B.³,Dooley Steven⁴,Gaston Kevin⁵,Giannelli Gianluigi⁶^ORCID,Rodrigues Cecilia M. P.³,Lozano Elisa⁷,Mancarella Serena⁶^ORCID,Segatto Oreste⁸,Vaquero Javier¹⁹,Marin Jose J. G.⁷^ORCID,Coulouarn Cédric¹⁰^ORCID

Affiliation:

1. Sorbonne Université, INSERM, Centre de Recherche Saint‐Antoine (CRSA) Paris France

2. Clinic of Gastroenterology and Hepatology Università Politecnica delle Marche, Ospedali Riuniti - University Hospital Ancona Italy

3. Research Institute for Medicines (iMed.ULisboa) Universidade de Lisboa Lisbon Portugal

4. Department of Medicine II, Molecular Hepatology Section Heidelberg University Mannheim Germany

5. Division of Cancer and Stem Cells, School of Medicine University of Nottingham, Queen's Medical Centre Nottingham UK

6. National Institute of Gastroenterology “Saverio de Bellis”, Research Hospital Bari Italy

7. Experimental Hepatology and Drug Targeting (HEVEFARM) IBSAL, University of Salamanca Salamanca Spain

8. Unit of Oncogenomics and Epigenetics IRCCS Regina Elena National Cancer Institute Rome Italy

9. Sorbonne Université, CNRS, Ecole Polytech., Univ. Paris‐Sud, Observatoire de Paris, Université Paris‐Saclay, PSL Research University Paris France

10. Inserm, Univ Rennes, Inra, Institut NuMeCan (Nutrition Metabolisms and Cancer) Rennes France

Funder

Institut National de la Santé et de la Recherche Médicale

Thailand Research Fund

Université de Rennes 1

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/liv.14102

Reference213 articles.

1. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

2. Tumour cell–derived extracellular vesicles interact with mesenchymal stem cells to modulate the microenvironment and enhance cholangiocarcinoma growth

3. STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression

4. STAT3 overexpression promotes metastasis in intrahepatic cholangiocarcinoma and correlates negatively with surgical outcome;Yang XW;Oncotarget,2017

5. Blocking of the EGFR‐STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma;Zhang C;Exp Ther Med,2018

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Huaier inhibits cholangiocarcinoma cells through the twist1/FBP1/Wnt/β-catenin axis;Molecular Biology Reports;2024-07-23

2. Autotaxin–Lysophosphatidate Axis: Promoter of Cancer Development and Possible Therapeutic Implications;International Journal of Molecular Sciences;2024-07-15

3. Trilobolide-6-O-isobutyrate exerts anti-tumor effects on cholangiocarcinoma cells through inhibiting JAK/STAT3 signaling pathway;Heliyon;2024-03

4. Advances in targeted therapy of cholangiocarcinoma;Annals of Medicine;2024-02-15

5. TGFβ-induced long non-coding RNA LINC00313 activates Wnt signaling and promotes cholangiocarcinoma;EMBO Reports;2024-02-08